Compositions of G-CSF and TNF-BP for prophylaxis and treatment o

Details Compositions of G-CSF and TNF-BP for prophylaxis and treatment o Compositions of G-CSF and TNF-BP for prophylaxis and treatment o

1995-01-23

1998-07-07

Scheiner, Toni R.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 2, 514885, 514921, 424 851, 424810, 4241341, 530350, 530351, C07K 14715, C07K 1453, A61K 3816, A61K 3819

Patent

active

057768951

ABSTRACT:
The present invention is directed to products containing G-CSF and a TNF binding protein and compositions of G-CSF and TNF-BP, and methods of treating and/or preventing septic shock by administering the products and compositions of the invention.

REFERENCES:
patent: 4810643 (1989-03-01), Souza
patent: 4985241 (1991-01-01), Zimmerman et al.
patent: 4999291 (1991-03-01), Souza
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
Layton JE et al (1993) Lympholine & Cytokine Res 12(5):327.
Aderka, D. Cytokine & Growth Factor Reviews vol. 7 No. 3 pp. 231-240 1996.
Natason C. et al (1994) Annals of Internal Medicine 120(9):771-783.
Rhein, R. (1993) Biotechnology, Newswatch Oct. 3, pp. 2-3.
Stephson, J. (1996) JAMA 275(11):823-824.
Evans TJ et al (1994) J. Exp Med 180(6):2173-2179.
Satake-Ishikawa et al, Cell Struct. and Function 17:157-160 "Chem. Mod. of rG-CSF by PEG increases its biol. activity in vivo" (1992).
Ashkenazi, et al., Proceedings Of The National Academy of Sciences, vol. 88, No. 23, pp. 10535-10539 (1991).
Teng, et al., Prevention of Runting and Cachexia by a Chimeric TNF Receptor-Fc Protein, Clinical Immunology and Immunopathology, vol. 69, No. 2, pp. 215-222, (1993).
English Abstract for Document B6 Patent No. JP 04-164099 (1992).
Gorgen et al., J. Immunol. 149:918-924 (1992) "Granulocyte colony-stimulating factor treatment protects rodents against . . . ".
Lesslauer et al., Eur. J. Immunol. 21:2883-2886 (1991) "Recombinanat soluble tumor necrosis factor receptor proteins protect mice . . . ".
Zanetti et al., J. Immunol. 148:1890-1897 (1992) "Cytokine production after intravenous or peritoneal gram-negative . . . ".
Loetscher, et al., International Congress Series Excepta Medical 2: 455-662 (1993) "Efficacy of a chimeric TNFR-IgG fusion protein . . . ".
Calandra, et al., Progress in Clinical and Biological Research 367: 141-159 (1991) "Anti-lipopolysaccharide and anti-tumor necrosis . . . ".
Niven, et al., J. of Controlled Release 32:177-189 (1994) "Pulmonary absorption of polyethylene glycolated recombinanat human . . . ".

Affiliated with

Also associated with

Rating

Compositions of G-CSF and TNF-BP for prophylaxis and treatment o does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions of G-CSF and TNF-BP for prophylaxis and treatment o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of G-CSF and TNF-BP for prophylaxis and treatment o will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1205893